Peroxisome Proliferator-activated Receptor Agonist Rosiglitazone On Human Uterine Leiomyoma Cells

Objective:To explore the leiomyoma cells growth inhibition induced by a peroxisome proliferator activated receptor-Y activator rosiglitazone and its molecular mechanism.and to explore the expression of PPARγ,Bax,Bcl-2 mRNA, and the suppressive effect of rosilitazone on the proliferation and apoptosis of uterine leiomyoma cells in vitro. Our purpose was to explore the possible mechanism of uterine leiomyoma, and the possible to inhibit the growth of uterine leiomyoma, and prompt clinical application of PPAR Y agonist treatment of uterine leiomyma potential.Methods:Uterine leiomyoma cells were cultered in vitro,after the action of rosigliatzone with different concentration,MTT was used to examne the inhibition activity of uterine leiomyoma cells.RT-PCR was used to determine the expression of the PPARγand of the apoptosi genes Bax,Bcl-2 in uterine leiomyoma.Result:(1)The uterine leiomyma cells were got by using collagenase dissection and identified by immunocytochemistry.(2)MTT method showed that:The treatment after2,48,72h(P< 0.05) resulted in an inhibition of the cell growths with (5 X 10-6,5×10-7 mol/L) rosiglitazone(P< 0.05),and there were no significant difference between eath other with 5 X 10-8mol/Lrosiglitazone (P> 0.05). The treatment with rosiglitazone(5 X 10-6,5 X 10-7,5 X 10-8mol/L) resulted in an inhibition of the cell growths after 72,48 house (P< 0.05),and there were no significant difference between each other in the treatment of 24h(P> 0.05).(3)Semi-quantitative RT-PCR results showed that:Rosiglitazone(5 X 10-6,5 X 10-7,5 X 10-8mol/L) affect uterine leiomyma cells 72h,will increase the expression of PPARγ,Bax,reduce the expression of Bcl-2,and its role is adose dependent manner., showing apparent activation inhibition.Conclusion:(1)Rosiglitazone significantly inhibited the in vitro cultured human uterine leiomyoma cell proliferation, with the increase in drug dose and the extension of the time, uterine leiomyoma cell proliferation and activation are inhibited, show a dose-and time-dependent.(2) Rosiglitazone can suppress the cell proliferation partly through the regulations of PPAR-γ,Bax and Bcl-2 expressions. The cross-talk between the signal pathways of PPAR-y and Bax,Bcl-2 may be involved in the process. (3)PPARγligands may be of potential use for uterine leiomyoma treantment.